182 related articles for article (PubMed ID: 22751086)
1. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia.
Stryjer R; Ophir D; Bar F; Spivak B; Weizman A; Strous RD
Clin Neuropharmacol; 2012; 35(4):161-4. PubMed ID: 22751086
[TBL] [Abstract][Full Text] [Related]
2. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
4. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
Sharma T; Reed C; Aasen I; Kumari V
Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
[TBL] [Abstract][Full Text] [Related]
5. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R
J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
[TBL] [Abstract][Full Text] [Related]
7. Effect of piracetam on ECT-induced cognitive disturbances: a randomized, placebo-controlled, double-blind study.
Tang WK; Ungvari GS; Leung HC
J ECT; 2002 Sep; 18(3):130-7. PubMed ID: 12394531
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial.
Prakash J; Kotwal A; Prabhu H
J ECT; 2006 Sep; 22(3):163-8. PubMed ID: 16957530
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
10. Autobiographical and subjective memory with right unilateral high-dose 0.3-millisecond ultrabrief-pulse and 1-millisecond brief-pulse electroconvulsive therapy: a double-blind, randomized controlled trial.
Mayur P; Byth K; Harris A
J ECT; 2013 Dec; 29(4):277-82. PubMed ID: 24263273
[TBL] [Abstract][Full Text] [Related]
11. Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: is it a safe and effective combination?
Flamarique I; Castro-Fornieles J; Garrido JM; de la Serna E; Pons A; Bernardo M; Baeza I
J Clin Psychopharmacol; 2012 Dec; 32(6):756-66. PubMed ID: 23131877
[TBL] [Abstract][Full Text] [Related]
12. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
13. Effect of Memantine on Cognitive Performance in Patients Under Electroconvulsive Therapy: A Double-Blind Randomized Clinical Trial.
Alizadeh NS; Maroufi A; Jamshidi M; Hassanzadeh K; Gharibi F; Ghaderi E
Clin Neuropharmacol; 2015; 38(6):236-40. PubMed ID: 26536019
[TBL] [Abstract][Full Text] [Related]
14. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
16. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
17. Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: A placebo controlled trial.
Abbasinazari M; Adib-Eshgh L; Rostami A; Beyraghi N; Dabir S; Jafari R
Asian J Psychiatr; 2015 Jun; 15():5-9. PubMed ID: 25998093
[TBL] [Abstract][Full Text] [Related]
18. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
Mäurer M; Ortler S; Baier M; Meergans M; Scherer P; Hofmann W; Tracik F
Mult Scler; 2013 Apr; 19(5):631-8. PubMed ID: 23069874
[TBL] [Abstract][Full Text] [Related]
19. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
[TBL] [Abstract][Full Text] [Related]
20. Double-blind randomized controlled study comparing short-term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania.
Hiremani RM; Thirthalli J; Tharayil BS; Gangadhar BN
Bipolar Disord; 2008 Sep; 10(6):701-7. PubMed ID: 18837864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
